Martine Keenan (Epichem) The Role of Cyp51 inhibitors in Chagas disease research
BMGF Global Health compound design webinar July 23rd 2020.
The suitability of sterol 14α-demethylase, or CYP51, as a drug target for inhibiting growth and replication of T. cruzi to treat Chagas disease was a great hope to the field over a decade ago. Whilst research programs targeting this mechanism have not delivered a new chemical entity to the clinic, many useful lessons have been learnt along the way to advance the field. This webinar will describe research and learnings from T. cruzi medicinal chemistry programs undertaken by DNDi’s Chagas disease Consortium that shape our approach to Chagas disease drug discovery efforts today, including the ideal profile of screening hits, identifying T. cruzi CYP51 pharmacophores, and a screening cascade for compound triage.
